Source:http://linkedlifedata.com/resource/pubmed/id/18941430
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2008-11-25
|
pubmed:abstractText |
Given the severe shortage of deceased-donor organs in Japan, the use of living-donor kidney transplantation (LKT) strategies, such as ABO-incompatible living-donor kidney transplantation, has expanded rapidly. ABO-incompatible LKT was initially performed following splenectomy and antibody removal; however, immunosuppressive protocols for ABO-incompatible LKT have changed markedly over recent years in Japan. Mycophenolate mofetil, calcineurin inhibitors and corticosteroids are now used to achieve desensitization before transplantation, and thereby suppress acute antibody-mediated rejection. In addition, many institutions now use anti-CD20 antibody (rituximab) instead of splenectomy, which seems to have markedly reduced the incidence of acute antibody-mediated rejection. ABO-incompatible LKT recipients in Japan typically undergo 2-4 sessions of plasma exchange or double-filtration plasmapheresis before transplantation to remove anti-ABO antibodies. In contrast to many Western countries, antibody removal is not routinely performed after kidney transplantation in Japan. Among 1,012 ABO-incompatible LKTs carried out at 92 Japanese institutions during the period 1989-2006, 1-year, 3-year, 5-year and 10-year patient survival rates were 95%, 93%, 91% and 87%, respectively, and the corresponding graft survival rates were 90%, 86%, 80% and 63%, respectively. These data indicate that the outcomes of ABO-incompatible LKT are comparable to those of ABO-compatible LKT. This Review summarizes Japan's experience with ABO-incompatible LKT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1745-8331
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
682-92
|
pubmed:meshHeading |
pubmed-meshheading:18941430-ABO Blood-Group System,
pubmed-meshheading:18941430-Acute Disease,
pubmed-meshheading:18941430-Desensitization, Immunologic,
pubmed-meshheading:18941430-Graft Rejection,
pubmed-meshheading:18941430-Humans,
pubmed-meshheading:18941430-Japan,
pubmed-meshheading:18941430-Kidney Transplantation,
pubmed-meshheading:18941430-Living Donors,
pubmed-meshheading:18941430-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
Japan's experience with living-donor kidney transplantation across ABO barriers.
|
pubmed:affiliation |
Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita, Osaka, Japan. ichimaru@uro.med.osaka-u.ac.jp
|
pubmed:publicationType |
Journal Article,
Review
|